SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-23-014859
Filing Date
2023-05-02
Accepted
2023-05-02 16:09:44
Documents
14
Period of Report
2023-05-02
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arwr-20230502.htm   iXBRL 8-K 38420
2 EX-99.1 arwr-fq22023financialresul.htm EX-99.1 72163
6 image_0a.jpg GRAPHIC 66690
  Complete submission text file 0001628280-23-014859.txt   354007

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arwr-20230502.xsd EX-101.SCH 1929
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arwr-20230502_lab.xml EX-101.LAB 24849
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arwr-20230502_pre.xml EX-101.PRE 13064
8 EXTRACTED XBRL INSTANCE DOCUMENT arwr-20230502_htm.xml XML 12119
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Filer) CIK: 0000879407 (see all company filings)

IRS No.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38042 | Film No.: 23879017
SIC: 2834 Pharmaceutical Preparations